Thrombasthenia clinical trials
The registry lists 20 studies for Thrombasthenia across more than 10 countries. 6 are recruiting or about to start. 14 of them are mainly about Thrombasthenia (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-13.
Get an email when these change. Save the Thrombasthenia studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Novo Nordisk A/S (4) · Emory University (3) · University Hospital, Bordeaux (2) · Hemab ApS (2) · UMC Utrecht (1) · Roswell Park Cancer Institute (1) · Haemnet (1) · Rockefeller University (1)
What is being tested here
Drugs under test in Thrombasthenia studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Recombinant FVIIa | 1 | 0 | 2 |
| Abatacept | 0 | 0 | 1 |
| Cyclophosphamide | 0 | 0 | 1 |
| Fludarabine phosphate | 0 | 0 | 1 |
| Fludarabine | 0 | 0 | 1 |
| Alefacept | 0 | 0 | 1 |
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 2
Who these studies take
Of the 5 Thrombasthenia studies recruiting now, 4 (80%) set no upper age limit and 1 (20%) stop at 75 or younger. 4 (80%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 1 (20%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 3 (60%) | 3 (60%) |
| 18 | 5 (100%) | 5 (100%) |
| 30 | 5 (100%) | 5 (100%) |
| 40 | 5 (100%) | 5 (100%) |
| 50 | 5 (100%) | 5 (100%) |
| 65 | 5 (100%) | 5 (100%) |
| 75 | 4 (80%) | 4 (80%) |
| 85 | 4 (80%) | 4 (80%) |
Across all 20 studies, recruiting or not: 35% stop at 75 or younger and 20% at 65; 80% take children; 0% are for women only and 5% for men only; 10% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
What changed recently
From the registry's own updates since Oct 14, 2026.
Newly registered1
- A Phase 3 Evaluation of Sutacimig in Glanzmann ThrombastheniaNov 13, 2026NCT07935356
Studies
Recruiting first, then most recently updated. Showing 20 of 20. search them.
- A Phase 3 Evaluation of Sutacimig in Glanzmann ThrombastheniaRecruitingNCT07935356Phase 31 country
- Videomicroscopy for the Prediction of Bleeding in Constitutional Haemorrhagic DiseasesRecruitingNCT04119908Not applicable1 country
- ATHNdataset RegistryRecruitingNCT068205151 country
- Eptacog Beta in Glanzmann's (HeT_LFB-Strength-Study_FID531)RecruitingNCT07136857Phase 21 country
- The Genetics and Functional Basis of Inherited Platelet, White Blood Cell, Red Blood Cell, and Blood Clotting Disorders.RecruitingNCT002301651 country
- Multinational Glanzmann StudyNot yet recruitingNCT06204042
- A Phase 1/2 Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Glanzmann ThrombastheniaActive, not recruitingNCT06211634Phase 1/26 countries
- Targeting TFPI With Concizumab to Improve Haemostasis in Glanzmann Thrombasthenia Patients: an in Vitro StudyCompletedNCT06234813Not applicable1 country
- Anti-αIIbβ3 Immunization in Glanzmann Thrombasthenia: Prevalence and Associated Risk Factors: Thrombasthenia Anti-αIIbβ3 Antibodies Study (TAAS)CompletedNCT04595617Not applicable1 country
- Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood CancerTerminatedNCT03333486Phase 21 country
- Hematopoietic Stem Cell Transplant for High Risk HemoglobinopathiesTerminatedNCT02179359Not applicable1 country
- The Experiences of People Who Live With Glanzmanns Thrombasthenia.CompletedNCT053152321 country
- Prospective, Non-interventional Study to Evaluate Immunogenicity of AryoSevenCompletedNCT033729931 country
- Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Inherited Bleeding DisordersTerminatedNCT04548791Phase 1/25 countries
- Bone Marrow Transplant With Abatacept for Non-Malignant DiseasesCompletedNCT01917708Phase 11 country
- Alefacept and Allogeneic Hematopoietic Stem Cell TransplantationTerminatedNCT01319851Not applicable1 country
- A Study to Evaluate Safety and Efficacy of NovoSeven® in Patients With Glanzmann's Thrombasthenia in JapanCompletedNCT018767451 country
- Bioequivalence of NovoSeven® and a NovoSeven® Formulation Stable at Room Temperature in Healthy Male SubjectsCompletedNCT01561417Phase 11 country
- Observational Study on the Efficacy and Safety of NovoSeven® During "Real-life" Usage in GermanyCompletedNCT006973201 country
- Observational Registry of the Treatment of Glanzmann's ThrombastheniaCompletedNCT0147642315 countries